key: cord-0822047-dnawiw89
authors: Palmateer, Norah E.; Dickson, Elizabeth; Furrie, Elizabeth; Godber, Ian; Goldberg, David J.; Gousias, Petros; Jarvis, Lisa; Mathie, Lindsay; Mavin, Sally; McMenamin, Jim; McNeilly, Tom N.; Murcia, Pablo; Murray, Josie; Reid, Graeme; Robertson, Chris; Templeton, Kate; von Wissmann, Beatrix; Wallace, Lesley A.; Waugh, Craig; McAuley, Andrew
title: National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic
date: 2021-07-20
journal: Public Health
DOI: 10.1016/j.puhe.2021.07.006
sha: 2fae13f3f27e70ddf91bdf4027381ac63a2f6142
doc_id: 822047
cord_uid: dnawiw89

Objectives Studies that measure the prevalence of antibodies to SARS-CoV-2 (“seroprevalence”) are essential to understand population exposure to SARS-CoV-2 among symptomatic and asymptomatic individuals. We aimed to measure seroprevalence in the Scottish population over the course of the COVID-19 pandemic – from prior to the first recorded case in Scotland, through to the second pandemic wave. Study design Serial cross-sectional. Methods We tested 41,477 residual samples retrieved from primary and antenatal care settings across Scotland for SARS-CoV-2 antibodies over a 12-month period from December 2019-December 2020 (pre-rollout of COVID-19 vaccination). Five-weekly rolling seroprevalence estimates were adjusted for the sensitivity and specificity of the assays and weighted to reference populations. Temporal trends in seroprevalence estimates and weekly SARS-CoV-2 PCR positive notifications were compared. Results Five-weekly rolling seroprevalence rates were 0% until the end of March, when they increased contemporaneously with the first pandemic wave. Seroprevalence rates remained stable through the summer (range 3%–5%) during a period of social restrictions, following which they increased concurrently with the second wave, reaching 9.6% (95% CI 8.4%-10.8%) in week beginning 28th December 2020. Seroprevalence rates were lower in rural vs. urban areas (adjusted odds ratio[AOR] 0.70, 95% CI 0.61–0.79) and among individuals aged 20-39 and 60+ (AORs 0.74, 95% CI 0.64–0.86, and 0.80, 95% CI 0.69–0.91, respectively) relative to those aged 0-19 years. Conclusions After two waves of the COVID-19 pandemic, less than one in ten individuals in the Scottish population had antibodies to SARS-CoV-2. Seroprevalence may underestimate the true population exposure as a result of waning antibodies among individuals who were infected early in the first wave.

Study design: Serial cross-sectional. 10

Methods: We tested 41,477 residual samples retrieved from primary and antenatal care settings across 11

Scotland for SARS-CoV-2 antibodies over a 12-month period from December 2019-December 2020 (pre-12 rollout of COVID-19 vaccination). Five-weekly rolling seroprevalence estimates were adjusted for the 13 sensitivity and specificity of the assays and weighted to reference populations. Temporal trends in 14 seroprevalence estimates and weekly SARS-CoV-2 PCR positive notifications were compared. 15

Results: Five-weekly rolling seroprevalence rates were 0% until the end of March, when they increased 16 contemporaneously with the first pandemic wave. Seroprevalence rates remained stable through the 17 summer (range 3%-5%) during a period of social restrictions, following which they increased 18 concurrently with the second wave, reaching 9.6% (95% CI 8.4%-10.8%) in week beginning 28th 19

December 2020. Seroprevalence rates were lower in rural vs. urban areas (adjusted odds ratio [AOR] The first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Scotland was 29 reported on 1 March 2020. The country has since experienced two waves of COVID-19 (the disease 30 associated with SARS-CoV-2), which has resulted in one of the highest excess mortality rates worldwide. 31

Estimates of the proportion of individuals in the population who have been exposed to SARS-CoV-2 -32 both symptomatic and asymptomatic -are necessary to understand the progression of the pandemic to 33 date. Since PCR testing in the general population until recently has mainly been limited to those with 34 symptoms, seroprevalence studies, which measure antibodies to SARS-CoV-2, provide a means of 35 measuring population exposure. Furthermore, it is essential to have estimates of the extent of exposure 36 from wild-type infection prior to rollout of vaccination. Most population-based seroprevalence surveys 37 to date have focused on short time frames or sub-national populations; here, we examine serial cross-38 sectional estimates of seroprevalence over a 12-month period in the Scottish general population, using 39 residual blood samples from different sources. 40

Residual blood samples, originally collected for other purposes, were identified from primary care (i.e. 41 general practice) and antenatal care settings. Antenatal samples were retrospectively identified at 42 regional laboratories across Scotland that store specimens taken for infectious disease screening at 43

week 12 of pregnancy; these specimens are submitted from all antenatal settings in the regional health 44 authority areas ("National Health Service (NHS) Boards") that are covered by these laboratories. 45

Samples were available from ISO-week 1 (week beginning (w/b) 30 th December 2019), to ISO-week 26 46 (w/b 29 th June 2020); all available samples with sufficient volume were included (totaling 16,157).

Primary care samples were retrieved from regional laboratories, which receive samples from general 48 practices across the NHS Boards that they cover. Approximately 700 weekly samples were obtained 49 between ISO week 17 (w/b 20 th April 2020) and ISO-week 53 (w/b 28 th December 2020), totaling 25,320 50 J o u r n a l P r e -p r o o f samples. Primary care samples were selected according to an age/sex/NHS Board sampling frame 51 corresponding to the Scottish general population structure. Eleven and seven out of the 14 NHS Boards 52 in Scotland participated in the primary care and antenatal surveillance, respectively, covering 91% and 53 73% of the Scottish population. This analysis was restricted to samples up until the end of December 54 2020 in order to measure exposure to wild-type infection and not vaccine response: vaccination rollout 55 for target groups began in Scotland on 8 th December 2020; however, given the lag time between 56 exposure to vaccination and seroconversion, 1,2 antibodies resulting from vaccine response would likely 57 not be detectable in seroprevalence estimates until early January 2021. 58

Samples were anonymised prior to testing: only age (and sex for primary care samples) and NHS Board 59 were attached to the result. Primary care samples were sent to the Scottish Microbiology Reference 60 laboratory, where they were tested for the presence of anti-SARS-CoV-2 IgG antibodies using the 61 LIAISON®SARS-CoV-2 S1/S2 IgG assay (DiaSorin, Italy). Antenatal samples were tested at the regional 62 laboratories where they were stored using either the Abbott (Abbott SARS-CoV-2 N IgG), Roche (Roche 63

Elecsys Anti-SARS-CoV-2 N IgM/ IgG) or Siemens (Siemens Atellica IM 1300 S1 total antibody) assay, 64 depending on the laboratory where testing was undertaken. We identified positive results in the 65 antenatal samples in the weeks prior to the first confirmed case of COVID-19 in Scotland (n=9). While 66 there is evidence to suggest that COVID-19 was circulating before it was first identified in numerous 67 countries, 3,4 we considered the possibility that these were false positives and therefore confirmatory 68 testing was undertaken by re-testing on a different assay (Roche/Siemens) to the original (Abbott). 69

Samples were re-tested (one re-test per sample) in ascending chronological order until 10 consecutive 70 negative samples were obtained. The confirmatory result is presented here. 71

Local unpublished evaluations determined sensitivities and specificities of the assays (Table 1) . 72 population (the Scottish general population for primary care; maternities in Scotland for antenatal), 74 using bootstrap methods. Five-weekly rolling seroprevalence estimates were calculated to smooth out 75

week-to-week variation; these were plotted against the last week in each five-week grouping (e.g. 76 weeks 17-21 were plotted at week 21). Seroprevalence estimates were compared to SARS-CoV-2 PCR 77 positive notifications obtained from Public Health Scotland. Weekly totals for the latter were plotted 78 against a 3-week lag, to account for the delay between exposure to the virus and seroconversion 79 (estimated to be between 2-4 weeks). 6 Chi-square tests for trend (ꭓ 2 trend ) were conducted on the weekly 80 unadjusted seroprevalence data to determine statistical significance. Mantel-Haenszel odds ratios, 81 adjusted for ISO-week, were calculated to examine differences in seroprevalence by sex, age group, and 82 region (categorized into urban/rural) among the primary care samples. 83

Rolling 5-weekly seroprevalence rates (Figure 1a December 2020) (ꭓ 2 trend =23.28, p<0.001). This second increase in seroprevalence occurred concurrently 93 with the increase in SARS-CoV-2 cases associated with the second wave of the pandemic (Figure 1b) . 94 Seroprevalence rates by sex, age, and region are presented in the supplementary files. Seroprevalence 95

Seroprevalence was lower in the 20-39 and 60+ age groups compared to those aged 0-19 years (p<0.001 97 and p=0.0013, respectively; Table S1, Figure S2 ). Regional comparisons showed higher seroprevalence in 98 NHS Boards with large urban centres compared to those with primarily rural populations (p<0.001; Table  99 1, Figures S3 and S4) . A second sharp increase in seroprevalence was observed from October, coinciding with the second 107 pandemic wave. Our seroprevalence findings are consistent with the PCR data during the period of 108 restrictions from March to October; it is likely that the infection rates across this period, which 109 otherwise would have caused an increase in seroprevalence, were counterbalanced by waning antibody 110 among individuals who had been exposed early on in the pandemic. 7 We also found that seroprevalence 111 rates were higher in urban areas and in those aged 0-19 years. 112

Despite two waves of infection, our estimate of seroprevalence of 9.6% at the end of December 2020 113 suggests that the majority of the Scottish population has still not been exposed to SARS-CoV-2. This 114 finding is corroborated by seroprevalence data from other western countries in similar phases of the 115 pandemic: a study of blood donors/pregnant women in Stockholm, Sweden, showed approx. 15% 116 seroprevalence by mid-Dec 2020 (this is comparable to our estimates from urban areas such as Greater 117

Glasgow, which approached 13% by end December). 8 A household survey from Geneva found a slightly 118 higher seroprevalence of 21%. 9 Seroprevalence may, however, underestimate true population exposure for several reasons: lack of 120 antibody persistence 7 and the role of other immune responses in neutralizing infection (there is 121 evidence that some individuals who are exposed to SARS-CoV-2 do not develop measurable antibodies, 122 suggesting the role of cellular immunity). 10 The ability of binding antibodies to confer immunity to SARS-123

CoV-2 infection is also not known and antibody neutralisation activity may be less among asymptomatic 124 individuals. 11 125

Limitations of our study include the uncertainty in the sensitivity and specificity of the assays, and 126 uncertainty with regard to the representativeness of our samples with regard to the general Scottish 127 population. To address this, we weighted the data to standard reference populations to account for any 128 oversampling according to age/sex/geography; furthermore, primary care results are very consistent 129 with data from a general household survey undertaken across Scotland. 12 The seroprevalence rates from 130 antenatal samples were slightly lower than those from primary care: we hypothesise that pregnant 131 women were taking extra precautions to avoid infection in the context of the COVID-19 pandemic. 132 133

Acknowledgements: The authors would like to thank the real-time epidemiology team at Public Health 135

Scotland for the PCR data; staff at all the participating regional laboratories; and the National Serology 136

Strategy Group for their oversight of the study. 137 J o u r n a l P r e -p r o o f 

Safety and 146 immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a 147 phase 1/2, single-blind, randomised controlled trial

Phase I/II study of COVID-149 19 RNA vaccine BNT162b1 in adults

Emergence of genomic 151 diversity and recurrent mutations in SARS-CoV-2

Tracking the onset date of the community spread of SARS-CoV-153 2 in western countries

Estimating prevalence using an imperfect test

Profiling Early Humoral Response to Diagnose 156 Novel Coronavirus Disease (COVID-19)

Do antibody positive healthcare 158 workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large 159 multi-centre prospective cohort study (the SIREN study)

Seropositivity in 163 blood donors and pregnant women during 9-months of SARS-CoV-2 transmission in Stockholm

Seroprevalence of anti-167 SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study

Covid-19: Do many people have pre-existing immunity?

SARS-CoV-2 serosurveillance 171 in a patient population reveals differences in virus exposure and antibody-mediated immunity 172 according to host demography and healthcare setting

Office for National Statistics. Coronavirus (COVID-19) Infection Survey, antibody data for the UK 174